Table 1.
Round 1: Questionnaire development |
Round 2 |
Round 3 |
||||||
---|---|---|---|---|---|---|---|---|
n | Question |
Mean | SD | Intermediate consensus | Mean | SD | Final consensus | |
n | n | n | n | |||||
Open question: which are appropriate referrals to CR in the COVID-19 era? | ||||||||
1 | Primary diagnosis: CV disease | All patients with primary cardiovascular diagnosis of ‘post-ACS and post-primary PCI’ should be referred to CR, independently from the history of COVID-19 | 3.74 | 2.86 | For | 4.22 | 2.11 | For (confirmed) |
2 | All patients with primary cardiovascular diagnosis of ‘chronic coronary syndromes’ should be referred to CR, independently from the history of COVID-19 | 2.77 | 3.05 | NC | 3.14 | 2.51 | For (new) | |
3 | All patients with primary cardiovascular diagnosis of ‘coronary artery or valve heart surgery’ should be referred to CR, independently from the history of COVID-19 | 3.41 | 2.95 | For | 3.91 | 2.27 | For (confirmed) | |
4 | All patients with primary cardiovascular diagnosis of ‘chronic heart failure’ should be referred to CR, independently from the history of COVID-19 | 3.35 | 2.85 | For | 3.96 | 2.14 | For (confirmed) | |
5 | All patients with primary cardiovascular diagnosis of ‘cardiac transplantation’ should be referred to CR, independently from the history of COVID-19 | 2.74 | 3.11 | NC | 3.09 | 2.59 | For (new) | |
6 | All patients with primary cardiovascular diagnosis of ‘device implantation’ should be referred to CR, independently from the history of COVID-19 | 2.14 | 3.43 | NC | 2.64 | 3.09 | NC | |
7 | All patients with primary cardiovascular diagnosis of ‘presence of ventricular assist device’ should be referred to CR, independently from the history of COVID-19 | 2.48 | 3.60 | NC | 3.13 | 2.96 | For (new) | |
8 | All patients with primary cardiovascular diagnosis of ‘peripheral artery disease’ should be referred to CR, independently from the history of COVID-19 | 2.04 | 3.15 | NC | 2.57 | 2.86 | NC | |
9 | Only patients with ischaemic heart disease as primary cardiovascular qualifying diagnosis to CR should be referred to CR, independently from the history of COVID-19 | −2.26 | 3.60 | NC | −2.26 | 3.60 | NC | |
10 | Patients with CHF should not be referred’ as referral of this group (i.e. the exercise programme) is more controversial due to the high risk of centre-based CR and safety concerns of telerehabilitation | −1.73 | 3.79 | NC | −2.09 | 3.49 | NC | |
11 | Aged/frail patients should not be referred’ as referral of this group (i.e. the exercise programme) is more controversial due to the high risk of centre-based CR and safety concerns of telerehabilitation | −0.82 | 3.74 | NC | −1.09 | 3.45 | NC | |
12 | Priorities on which primary cardiovascular qualifying diagnosis should be referred to CR, independently from the history of COVID-19, should be defined at a local level (Hospital/Institution/CR facility) | 2.77 | 3.04 | NC | 2.95 | 2.85 | For (new) | |
13 | Only patients with a primary cardiovascular qualifying diagnosis to CR and a history of COVID-19 should be referred to CR | −2.04 | 4.19 | NC | −2.39 | 3.90 | NC | |
14 | CV patients referred to CR should have no history of COVID-19 | −2.39 | 3.07 | NC | −2.74 | 2.61 | Against (new) | |
15 | Patients referred with a primary qualifying diagnosis for CR and a history of COVID-19 are limited to those having experienced invasive ventilation | −3.30 | 2.69 | Against | −3.30 | 2.69 | Against (confirmed) | |
16 | Patients referred with a primary qualifying diagnosis for CR and a history of COVID-19 are limited to those having experienced non-invasive ventilation | −3.26 | 2.78 | Against | −3.70 | 2.14 | Against (confirmed) | |
17 | Patients referred with a primary qualifying diagnosis for CR and a history of COVID-19 are limited to those having experienced stay in ICUs | −2.96 | 3.05 | NC | −3.39 | 2.54 | Against (new) | |
18 | Patients referred with a primary qualifying diagnosis for CR and a history of COVID-19 are limited to those having experienced hypoxia | −3.35 | 2.69 | Against | −3.78 | 2.00 | Against (confirmed) | |
19 | Patients referred with a primary qualifying diagnosis for CR and a history of COVID-19 are limited to those having experienced viral pneumonia | −3.70 | 2.12 | Against | −3.70 | 2.12 | Against (confirmed) | |
20 | Patients referred with a primary qualifying diagnosis for CR and a history of COVID-19 are limited to those having experienced any kind of symptom | −3.00 | 2.91 | Against | −3.00 | 2.91 | Against (confirmed) | |
21 | Patients referred with a primary qualifying diagnosis for CR and a history of COVID-19 are limited to those aged >75 and/or frail, whichever symptoms of COVID-19 | −3.39 | 2.81 | Against | −3.43 | 2.76 | Against (confirmed) | |
22 | Primary diagnosis: COVID-19 | COVID-19 patients should be referred to CR, independently from the history of CV disease | −2.43 | 3.62 | NC | −2.78 | 3.23 | NC |
23 | COVID-19 patients with pre-existing cardiovascular disease should be referred to CR | 1.17 | 3.73 | NC | 1.09 | 3.65 | NC | |
24 | COVID-19 patients with multiple CV risk factors should be referred to CR | 1.64 | 3.51 | NC | 1.55 | 3.45 | NC | |
25 | COVID-19 patients complicated by one or more adverse cardiac symptoms/events (angina pectoris, ACS, exacerbation of heart failure, cardiogenic shock, myocarditis, arrhythmias, resuscitated SCD, pericarditis/cardiac tamponade, and/or arterial/venous thromboembolic events) should be referred to CR | 3.68 | 2.68 | For | 3.68 | 2.68 | For (confirmed) | |
26 | COVID-19 patients requiring percutaneous coronary intervention and/or CIED implantation should be referred to CR | 3.50 | 2.52 | For | 3.50 | 2.52 | For (confirmed) | |
27 | COVID-19 patients developing pulmonary arterial hypertension should be referred to CR | 2.91 | 2.45 | For | 2.91 | 2.45 | For (confirmed) | |
28 | COVID-19 patients with prolonged stay in ICU should be referred to CR | 0.95 | 4.04 | NC | 0.86 | 3.97 | NC | |
29 | COVID-19 patients developing markedly reduced exercise tolerance should be referred to CR | 1.59 | 3.95 | NC | 1.50 | 3.89 | NC | |
30 | COVID-19 patients developing cardiovascular complications from therapeutic agents should be referred to CR | 2.41 | 3.19 | NC | 2.32 | 3.14 | NC | |
31 | COVID-19 patients with coagulation alterations should be referred to CR | −0.09 | 4.13 | NC | −0.27 | 3.98 | NC | |
Consensus rate: 39% | Consensus rate: 58% | |||||||
Comments:
|
||||||||
Open question: which are the optimal timing and setting of CR in the COVID-19 era? | ||||||||
32 | Patients without history of COVID | In patients without history of COVID there is no need to modify usual policies/recommendations for timing and setting | 1.78 | 3.72 | NC | 2.30 | 3.28 | NC |
33 | In patients without history of COVID there is need for fast track (time from referral to entry <15 days) by CR centres | 1.78 | 3.23 | NC | 2.13 | 2.87 | NC | |
34 | In patients without history of COVID there is need for delayed track by CR centres | −1.70 | 3.55 | NC | −2.26 | 3.25 | NC | |
35 | In patients without history of COVID the home environment should be preferred to limit people’s movements | 1.70 | 2.57 | NC | 2.09 | 2.15 | NC | |
36 | In patients without history of COVID the outpatient setting should be preferred to avoid contacts with hospitalized patients and health operators | 2.87 | 2.40 | For | 2.87 | 2.40 | For (confirmed) | |
37 | Patients with history of COVID | In COVID-19 patients CR (mainly exercise component) should begin during the acute phase of the viral disease if the patient is not haemodynamically unstable | −3.10 | 3.06 | Against | −3.48 | 2.44 | Against (confirmed) |
38 | In COVID-19 patients CR should begin after clinical recovery of pneumonia | 1.00 | 3.86 | NC | 1.33 | 3.61 | NC | |
39 | In COVID-19 patients CR should begin after radiologic recovery of pneumonia | −0.14 | 3.80 | NC | −0.38 | 3.53 | NC | |
40 | In COVID-19 patients CR should begin after resolution of COVID-19 induced hypoxia | 2.14 | 3.34 | NC | 2.29 | 3.42 | NC | |
41 | In COVID-19 patients CR should begin when no more clinical signs | 0.38 | 4.17 | NC | 0.95 | 3.77 | NC | |
42 | In COVID-19 patients CR should begin after the end of COVID-19 treatment regimen | −0.33 | 3.75 | NC | −0.24 | 3.65 | NC | |
43 | In COVID-19 patients CR should begin after NIV has been stopped | 0.00 | 4.10 | NC | 0.33 | 3.80 | NC | |
44 | In COVID-19 patients CR should begin when the P/f value is above 100 | −1.50 | 2.50 | NC | −1.41 | 2.45 | NC | |
45 | In COVID-19 patients CR should begin when the P/f value is above 200 | 0.00 | 2.48 | NC | 0.47 | 2.12 | NC | |
46 | In COVID-19 patients CR should begin when the P/f value is above 300 | 1.31 | 2.50 | NC | 1.24 | 2.44 | NC | |
47 | In COVID-19 patients the beginning of CR is independent from arterial blood gas parameters | −1.71 | 3.36 | NC | −1.95 | 3.02 | NC | |
48 | In COVID-19 patients CR should begin after two negative nasopharyngeal specimens for COVID-19 | 1.43 | 3.80 | NC | 1.52 | 3.66 | NC | |
49 | In COVID-19 patients CR should always comprise a first residential step | −0.68 | 3.17 | NC | −0.68 | 3.17 | NC | |
50 | In COVID-19 patients CR should always comprise an outpatient step | 0.64 | 3.35 | NC | 0.64 | 3.35 | NC | |
51 | In COVID-19 patients CR should be always offered as home-rehabilitation or mixed programmes when appropriate (if available) | 2.33 | 3.14 | NC | 2.43 | 3.19 | NC | |
52 | In COVID-19 patients enrolled in ambulatory or home-rehabilitation programmes, digital health tools should be integrated by tracing systems (Gps) | 2.18 | 3.08 | NC | 2.18 | 3.08 | NC | |
Consensus rate: 10% | Consensus rate: 10% | |||||||
Comments:
|
||||||||
Open question: which are the core components of CR in the COVID-19 era? | ||||||||
53 | Patients without history of COVID | In patients without history of COVID there is no need to modify usual policies/recommendations for core components delivery | 1.87 | 4.30 | NC | 2.17 | 4.01 | NC |
54 | In patients without history of COVID there is need to exclude the presence of COVID-19 | 2.61 | 2.87 | NC | 2.65 | 2.42 | For (new) | |
55 | In patients without history of COVID there is need to modify the core component ‘patient assessment’ | −0.87 | 4.04 | NC | −0.78 | 3.97 | NC | |
56 | In patients without history of COVID there is need to modify the core component ‘physical activity counselling’ | −0.95 | 3.80 | NC | −0.86 | 3.72 | NC | |
57 | In patients without history of COVID there is need to modify the core component ‘exercise training’ | −1.09 | 4.01 | NC | −1.18 | 3.89 | NC | |
58 | In patients without history of COVID there is need to modify the core component ‘diet/nutritional counselling’ | −2.91 | 2.96 | NC | −2.82 | 2.92 | NC | |
59 | In patients without history of COVID there is need to modify the core component ‘weight control management’ | −2.82 | 2.95 | NC | −2.82 | 2.95 | NC | |
60 | In patients without history of COVID there is need to modify the core component ‘lipid management’ | −2.77 | 2.96 | NC | −2.77 | 2.96 | NC | |
61 | In patients without history of COVID there is need to modify the core component ‘blood pressure management’ | −2.82 | 2.97 | NC | −2.82 | 2.97 | NC | |
62 | In patients without history of COVID there is need to modify the core component ‘smoking cessation’ | −2.91 | 2.83 | Against | −2.91 | 2.83 | Against (confirmed) | |
63 | In patients without history of COVID there is need to modify the core component ‘psychosocial management’ | −1.09 | 4.10 | NC | −1.00 | 4.03 | NC | |
64 | In patients without history of COVID there is need to include specific education on COVID-19 | 3.00 | 2.91 | For | 3.43 | 2.35 | For (confirmed) | |
65 | Patients with history of COVID | In patients with history of COVID-19 usual core components of CR delivery should be supplemented with other specific interventions | 3.09 | 3.10 | NC | 3.45 | 2.52 | For (new) |
66 | Core component ‘patient evaluation’. Patient evaluation should always comprise respiratory impairment and other COVID-19 features | 3.57 | 2.50 | For | 3.57 | 2.50 | For (confirmed) | |
67 | Core component ‘patient evaluation’. Chest X-ray should always be performed at beginning of the CR programme | 1.43 | 3.63 | NC | 1.90 | 3.30 | NC | |
68 | Core component ‘patient evaluation’. Nasopharyngeal specimen should always be performed at beginning of the CR programme | 1.05 | 3.97 | NC | 1.75 | 3.58 | NC | |
69 | Core component ‘patient evaluation’. Nasopharyngeal specimen should always be performed during of the CR programme | −0.80 | 3.65 | NC | −0.10 | 3.63 | NC | |
70 | Core component ‘patient evaluation’. Serology for COVID-19 should always be performed at beginning of the CR programme | −0.20 | 3.78 | NC | 0.45 | 3.61 | NC | |
71 | Core component ‘patient evaluation’. Serology for COVID-19 should always be performed during the CR programme | −2.45 | 3.43 | NC | −2.20 | 3.41 | NC | |
72 | Core component ‘patient evaluation’. Chest CT-scan should always be performed during the CR programme | −1.85 | 3.38 | NC | −1.75 | 3.31 | NC | |
73 | Core component ‘patient evaluation’. Arterial blood gas analysis should always be performed during the CR programme | −0.10 | 3.78 | NC | −0.19 | 3.72 | NC | |
74 | Core component ‘patient evaluation’. Direct testing of exercise capacity (CPET preferred) should always be performed at the start of the CR programme | 3.14 | 2.46 | For | 3.14 | 2.46 | For (confirmed) | |
75 | Core component ‘patient evaluation’. Indirect testing for exercise capacity should always be performed at the start of the CR programme | 2.38 | 2.96 | NC | 2.38 | 2.96 | NC | |
76 | Core component ‘patient evaluation’. Frailty should always be investigated during the CR programme | 3.05 | 2.80 | For | 3.05 | 2.80 | For (confirmed) | |
77 | Core component ‘patient evaluation’. History of COVID-19 (symptomatic or asymptomatic) among family and caregivers should always be collected | 2.90 | 3.05 | NC | 3.00 | 2.98 | For (new) | |
78 | In patients with history of COVID there is need to modify the core component ‘physical activity counselling’ | 1.10 | 4.18 | NC | 1.48 | 3.96 | NC | |
79 | Core component ‘exercise training’. IMT and/or other respiratory techniques should be included as normally indicated in the exercise training programme | 2.76 | 3.02 | NC | 2.76 | 2.58 | For (new) | |
80 | Core component ‘exercise training’. Strength training in COVID-19 should be included as normally indicated in CR programmes | 3.71 | 1.98 | For | 3.67 | 1.96 | For (confirmed) | |
81 | Core component ‘exercise training’. Strength training in frail COVID-19 patients should be included as normally indicated in CR programmes | 3.90 | 1.61 | For | 4.10 | 1.34 | For (confirmed) | |
82 | Core component ‘exercise training’. Low-to-moderate intense endurance training should always be executed in COVID-19 patients as normally indicated in CR programmes | 2.62 | 2.65 | NC | 2.62 | 2.65 | NC | |
83 | Core component ‘exercise training’. High-intensity interval training training should always be executed by COVID-19 patients as normally indicated in CR programmes | 0.24 | 3.45 | NC | 0.14 | 3.42 | NC | |
84 | Core component ‘exercise training’. All COVID-19 patients should execute structured exercise for at least 3 days/week | 3.19 | 2.50 | For | 3.19 | 2.50 | For (confirmed) | |
85 | Core component ‘exercise training’. All COVID-19 patients should maximize non-structured physical activity at home on daily basis | 3.76 | 1.87 | For | 3.76 | 1.87 | For (confirmed) | |
86 | Core component ‘exercise training’. During structured exercise training, cardiac telemetry is advised to all COVID-19 patients | 0.95 | 3.17 | NC | 0.76 | 3.91 | NC | |
87 | Core component ‘diet/nutritional counselling’. Nutritional intervention should be always particularly devoted to malnutrition as a consequence of prolonged immobilization and ventilatory support | 2.95 | 2.54 | For | 3.14 | 2.46 | For (confirmed) | |
88 | In patients with history of COVID there is need to modify the core component ‘weight control management’ | −0.71 | 4.04 | NC | −0.62 | 3.96 | NC | |
89 | In patients with history of COVID there is need to modify the core component ‘lipid management’ | −0.86 | 3.99 | NC | −0.76 | 3.91 | NC | |
90 | In patients with history of COVID there is need to modify the core component ‘blood pressure management’ | −1.33 | 3.83 | NC | −1.33 | 3.72 | NC | |
91 | In patients with history of COVID there is need to modify the core component ‘smoking cessation’ | −2.00 | 3.83 | NC | −1.91 | 3.78 | NC | |
92 | Core component ‘psychosocial management’. Lifestyle and psychosocial management should always particularly focused on smoking cessation | 3.00 | 2.94 | For | 3.27 | 2.62 | For (confirmed) | |
93 | Core component ‘psychosocial management’. Lifestyle and psychosocial management should always particularly focused on fear of infection | 2.73 | 3.19 | NC | 2.73 | 3.19 | NC | |
94 | Core component ‘psychosocial management’. Lifestyle and psychosocial management should always particularly focused on fighting of fake news | 3.36 | 2.26 | For | 3.36 | 2.26 | For (confirmed) | |
95 | Core component ‘psychosocial management’. Lifestyle and psychosocial management should always particularly focused on caregiver-limiting restrictive measures | 2.82 | 2.44 | For | 2.82 | 2.44 | For (confirmed) | |
96 | Core component ‘psychosocial management’. Lifestyle and psychosocial management should always particularly focused on working resume | 3.82 | 1.65 | For | 3.82 | 1.65 | For (confirmed) | |
Consensus rate: 32% | Consensus rate: 41% | |||||||
Comments:
|
||||||||
Open question: which are minimal structure-based metrics for CR programmes in the COVID-19 era? | ||||||||
97 | There is no need to modify usual policies/recommendations for structure-based metrics | −1.71 | 3.86 | NC | −1.77 | 3.78 | NC | |
98 | Residential CR facilities should have separated areas for confirmed COVID cases with regard to beds | 3.55 | 2.91 | For | 3.61 | 2.86 | For (confirmed) | |
99 | Residential CR facilities should have separated areas for confirmed COVID cases with regard to investigation rooms | 2.82 | 3.22 | NC | 2.83 | 3.14 | NC | |
100 | Residential CR facilities should have separated areas for confirmed COVID cases with regard to consultation areas | 3.05 | 3.18 | NC | 3.04 | 3.11 | NC | |
101 | Residential CR facilities should have separated areas for confirmed COVID cases with regard to exercise laboratories | 2.77 | 3.21 | NC | 2.83 | 3.14 | NC | |
102 | Residential CR facilities should have separated areas for confirmed COVID cases with regard to areas for exercise training | 2.68 | 3.27 | NC | 2.74 | 3.21 | NC | |
103 | Residential CR facilities should have separated areas for suspected COVID cases with regard to beds | 3.45 | 2.89 | For | 3.52 | 2.84 | For (confirmed) | |
104 | Residential CR facilities should have separated areas for suspected COVID cases with regard to investigation rooms | 2.68 | 3.03 | NC | 2.70 | 2.96 | NC | |
105 | Residential CR facilities should have separated areas for suspected COVID cases with regard to consultation areas | 2.91 | 3.10 | NC | 2.91 | 3.03 | NC | |
106 | Residential CR facilities should have separated areas for suspected COVID cases with regard to exercise laboratories | 2.64 | 3.11 | NC | 2.70 | 3.05 | NC | |
107 | Residential CR facilities should have separated areas for suspected COVID cases with regard to exercise training | 2.73 | 3.15 | NC | 2.78 | 3.09 | NC | |
108 | Residential CR facilities should have separated areas for COVID-free cases with regard to beds | 2.67 | 3.77 | NC | 2.77 | 3.72 | NC | |
109 | Residential CR facilities should have separated areas for COVID-free cases with regard to investigation rooms | 2.24 | 3.60 | NC | 2.27 | 3.52 | NC | |
110 | Residential CR facilities should have separated areas for COVID-free cases with regard to consultation areas | 2.24 | 3.60 | NC | 2.27 | 3.52 | NC | |
111 | Residential CR facilities should have separated areas for COVID-free cases with regard to exercise laboratories | 2.19 | 3.60 | NC | 2.27 | 3.53 | NC | |
112 | Residential CR facilities should have separated areas for confirmed COVID-frees with regard to areas for exercise training | 2.33 | 3.31 | NC | 2.41 | 3.25 | NC | |
113 | When performing CPET and/or other aerosol-generating testing, approved filters for protecting workers and other patients from exposure to SARS-CoV-2 should be available | 4.55 | 1.18 | For | 4.57 | 1.16 | For (confirmed) | |
114 | When performing CPET and/or other aerosol-generating testing, approved FFP-2 masks should be worn to protect workers and other patients from exposure to SARS-CoV-2 should be available | 4.68 | 0.89 | For | 4.70 | 0.88 | For (confirmed) | |
115 | Floor space during exercise training is increased from 4 to at least 6 m2 per patient | 3.41 | 3.00 | For | 3.48 | 2.95 | For (confirmed) | |
116 | In the CR facility PPE for health care workers should be worn | 4.17 | 1.50 | For | 4.21 | 1.47 | For (confirmed) | |
117 | A CR programme director to ensure proper organization and consistency of activities with national and institutional rules concerning SARS-CoV-2 infection prevention should be present | 4.09 | 1.44 | For | 4.13 | 1.42 | For (confirmed) | |
118 | The multidisciplinary team (cardiologist, nurse, exercise specialist, dietitian, psychologist) should be preserved as much as possible | 4.57 | 1.16 | For | 4.58 | 1.14 | For (confirmed) | |
119 | All members of the multidisciplinary should receive structured education on COVID-19 pathophysiology, clinical features, treatment, and prevention strategies | 4.52 | 1.31 | For | 4.54 | 1.28 | For (confirmed) | |
120 | The job description for every profession should be updated with specific COVID-19 oriented features | 3.65 | 2.52 | For | 3.71 | 2.48 | For (confirmed) | |
121 | The CR facility should provide dedicated operators and structured procedures facilitating contacts between patients and families in case of lockdown | 4.22 | 1.38 | For | 4.25 | 1.36 | For (confirmed) | |
Consensus rate: 44% | Consensus rate: 44% | |||||||
Comments:
|
||||||||
Open question: which are minimal process-based metrics for CR programmes in the COVID-19 era? | ||||||||
122 | There is no need to modify usual policies/recommendations for process-based metrics | −1.10 | 3.91 | NC | −1.19 | 3.78 | NC | |
123 | The CR unit should provide fast testing and quarantine until test results are available in case of suspected or confirmed new emerging COVID-19 cases among the referred population | 3.32 | 2.66 | For | 3.32 | 2.66 | For (confirmed) | |
124 | The suggested duration of CR programmes should be shortened (less than recommended 24 sessions), to increase the absolute number of CR programmes potentially delivered in a time unit | −0.77 | 3.75 | NC | −0.68 | 3.67 | NC | |
125 | Patients coming for a CPET or other aerosol-generating procedures are first need to confirm to be COVID-19 negative | 2.45 | 2.69 | NC | 2.41 | 2.65 | NC | |
126 | Plan at discharge and structured follow-up should be adapted to different phases of COVID-19 outbreak, in terms of timeline and diagnostic tools | 3.95 | 1.40 | For | 3.95 | 1.40 | For (confirmed) | |
127 | CR facilities should offer a continuing help-desk to discharged patients and their caregivers on how to manage the relationship between COVID-10 and cardiovascular conditions | 2.91 | 2.37 | For | 2.91 | 2.37 | For (confirmed) | |
128 | CR facilities with structured alternative models for delivering activities (tele-rehabilitation, facilitated home-based, web-based, supervised community-based, guided by digital health tools, etc.) should integrate the management of COVID-19 among programme contents | 4.09 | 1.38 | For | 4.09 | 1.38 | For (confirmed) | |
129 | CR facilities without structured alternative models for delivering activities should implement initial forms of tele-rehabilitation, with integration of management of COVID-19 among programme contents | 3.83 | 1.70 | For | 3.96 | 1.58 | For (confirmed) | |
Consensus rate: 62% | Consensus rate: 62% | |||||||
Comments:
|
||||||||
Open question: which are quality indicators for CR programmes in the COVID-19 era? | ||||||||
130 | There is no need to modify usual quality indicators in non-COVID patients | 1.96 | 3.77 | NC | 1.87 | 3.72 | NC | |
131 | There is no need to modify usual quality indicators in COVID patients | 0.91 | 3.96 | NC | 0.74 | 3.84 | NC | |
132 | % patients without history of COVID-19 eligible to CR referred after discharge to CR programme. The target should be maintained >80% as recommended by the 2020 position statement | 2.77 | 3.16 | NC | 2.73 | 2.61 | For (new) | |
133 | % patients without history of COVID-19 eligible to CR referred after discharge to CR programme. The target should be reduced to <80% due to logistic problems during COVID-19 pandemia | 0.05 | 4.03 | NC | 0.15 | 3.92 | NC | |
134 | % patients without history of COVID-19 eligible to CR, enrolled after discharge from COVID-19 units. The target should be >50% as recommended by the 2020 position statement | 2.33 | 3.35 | NC | 2.29 | 3.32 | NC | |
135 | % patients without history of COVID-19 eligible to CR, enrolled after discharge from COVID-19 units. The target should be reduced to <50% due to logistic problems during COVID-19 pandemia | −0.95 | 3.62 | NC | −0.85 | 3.53 | NC | |
136 | Patients without history of COVID-19, median waiting time from referral to start of CR. The target should be 14-28 days as recommended by the 2020 position statement | 2.29 | 3.47 | NC | 2.29 | 3.47 | NC | |
137 | Patients without history of COVID-19, median waiting time from referral to start of CR. The target should be reduced to <14–28 days, motivated by the necessity to avoid prolonged lack of contacts with health care providers | −0.33 | 3.77 | NC | −0.24 | 3.67 | NC | |
138 | Patients without history of COVID-19, % of CR uptake. The minimal target should be 24 sessions as recommended by the 2020 position statement | 3.64 | 2.38 | For | 3.73 | 2.31 | For (confirmed) | |
139 | Patients without history of COVID-19, % of CR uptake. The minimal target should be <24 sessions to increase the absolute number of CR programmes potentially delivered in a time unit | −1.62 | 4.07 | NC | −1.71 | 3.87 | NC | |
140 | % patients with history of COVID-19 eligible to CR referred after discharge to CR programme. The target should be maintained >80% as recommended by the 2020 position statement | 2.05 | 3.73 | NC | 2.00 | 3.70 | NC | |
141 | % patients with history of COVID-19 eligible to CR referred after discharge to CR programme. The target should be reduced to <80% due to logistic problems during COVID-19 pandemia | −1.35 | 3.62 | NC | −1.25 | 3.54 | NC | |
142 | % patients with history of COVID-19 eligible to CR, enrolled after discharge from COVID-19 units. The target should be >50% as recommended by the 2020 position statement | 1.86 | 3.55 | NC | 1.86 | 3.55 | NC | |
143 | % patients with history of COVID-19 eligible to CR, enrolled after discharge from COVID-19 units. The target should be reduced to <50% due to logistic problems during COVID-19 pandemia | −1.05 | 3.64 | NC | −0.95 | 3.56 | NC | |
144 | Patients with history of COVID-19, median waiting time from referral to start of CR. The target should be 14–28 days as recommended by the 2020 position statement | 2.33 | 3.40 | NC | 2.33 | 3.40 | NC | |
145 | Patients with history of COVID-19, median waiting time from referral to start of CR. The target should be reduced to <14–28 days, motivated by the necessity to avoid prolonged lack of contacts with health care providers | −1.38 | 3.65 | NC | −1.29 | 3.58 | NC | |
146 | Patients with history of COVID-19, % of CR uptake. The minimal target should be 24 sessions as recommended by the 2020 position statement | 2.64 | 3.11 | NC | 2.64 | 3.11 | NC | |
147 | Patients with history of COVID-19, % of CR uptake. The minimal target should be <24 sessions to increase the absolute number of CR programmes potentially delivered in a time unit | −1.90 | 3.60 | NC | −1.95 | 3.54 | NC | |
148 | % of CR drop-out due to de novo COVID-infection. The target should be <10% | 3.00 | 3.13 | NC | 3.00 | 3.13 | NC | |
149 | % of patients with evaluation of functional capacity by standard exercise testing. The target should be >50% | 2.86 | 3.17 | NC | 3.00 | 2.94 | For (new) | |
150 | % of patients with improvement of altered respiratory function and gas exchange following completion of CR. Target >90% | 2.82 | 2.81 | For | 2.82 | 2.81 | For (confirmed) | |
Consensus rate: 10% | Consensus rate: 20% | |||||||
Comments:
|
Including mean and standard deviation of the Likert scale. Consensus ‘for’ (mean score ≥2.5) or ‘against’ (mean score ≤2.5) each statement is indicated, while ‘NC’ (no consensus) indicates that consensus has not been reached (i.e. mean score between 2.4 and −2.4 or standard deviation crossing zero). The final consensus for each statement has been specified if confirmed or new, the latter indicating modification from round 2 to round 3. For each open question the consensus rate obtained at round 2 and 3 are provided. Comments have been edited for repetition, clarity, and anonymity, and served to present the whole picture of experts’ opinion.
ACS, acute coronary syndrome; CHF, chronic heart failure; CIED, cardiac implantable electronic device; CO%Hb, percentage of carboxyhaemoglobin; CPET, cardiopulmonary exercise testing; CR, cardiac rehabilitation; CV, cardiovascular; GPS, global positioning system; HTX, heart transplantation; ICU, intensive care unit; IMT, inspiratory muscle training; PCI, percutaneous coronary intervention; PPE, personal protective equipment; SCD, sudden cardiac death.